CTNNB1 and neoplasm: In cases of metastatic recurrence, CTNNB1 variants were identified in 20–33% (1/5 to 1/3, as only 3 of the 5 cases had a Sanger-sequencing-confirmed tumor CTNNB1-mutation) of samples, with a VAF of 1.1%.